Prospective Comparison of 18F-FDG and 18F-FET PET for Response Evaluation in Patients With Primary Central Nervous System Lymphoma

Asan Medical Center

Status

Unknown

Conditions

Patients With Suspected or Diagnosed Central Nervous System Lymphoma

Treatments

Drug: [18F]FET

Study type

Interventional

Funder types

Other

Identifiers

NCT05083936

FET-PCNSL

Details and patient eligibility

About

The overall goal of this imaging trial is to prospectively compare the usefulness of 18F-FDG PET and 18F-FET PET in evaluating treatment response and predicting prognosis in patients with central nervous system lymphoma.

Enrollment

30 estimated patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

In order to be eligible for participation in this trial, the subject must:

Be ≥ 19 years of age.
Patients diagnosed with central nervous system lymphoma by surgery/biopsy or suspected of central nervous system lymphoma by anatomical imaging examination such as MRI.
Patients who have results or are planning to examine 18F-FDG PET in the above patients.

Exclusion criteria

The subject must be excluded from participating in the trial if the subject fulfil any single criteria described below:

Pediatric and adolescent patients under 19 years of age.
The patient is pregnant, is attempting to become pregnant, or is nursing (breast-feeding) to children.
Patients with diagnosed or suspected lymphoma lesions in organs other than the cetral nervous system.
Based on the investigator's judgement, if the patient makes it impossible to collect complete data for a clinical trial due to personal or other reasons.
Patients who cannot stably have PET/CT due to claustrophobia, dyskinesia, anxiety disorder, seizure, etc.
Based on the investigator's judgement, if the patient has a serious and/or uncontrolled and/or unstable medical disease (e.g., congestive heart failure, acute myocardial infarction, severe lung disease, chronic renal disease or chronic liver disease, etc.)